10.01 - Respiratory infections and bronchiectasis最新文献_第3页

IL-4 levels in sputum correlate with increased mucus production and ciliary dysfunction 痰中IL-4水平与黏液生成增加和纤毛功能障碍相关

10.01 - Respiratory infections and bronchiectasis Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.2958

E. Cant, M. Bottier, M. Shuttleworth, F. Daudvohra, R. J. Urquhart, A. Gilmour, M. Crichton, D. Cassidy, T. Burgoyne, C. Hogg, J. Huang, J. Chalmers, A. Shoemark

引用次数: 1

Non-interventional, retrospective, multi-center, follow-up study evaluating the effect of the angiotensin II type 2 receptor agonist C21 on lung pathology in subjects previously hospitalised with COVID-19 非介入性、回顾性、多中心、随访研究评估血管紧张素II型2受体激动剂C21对既往住院患者COVID-19肺部病理的影响

10.01 - Respiratory infections and bronchiectasis Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.1051

R. Batta, G. Tornling, T. Bengtsson, A. Devaraj, R. Kashiva, A. Rajkondawar, K. Parmar, N. Bhalani, A. Bohra, A. Cohrt, C. Ganslandt

引用次数: 0

Azole resistance screening in Aspergillus species isolated from patients with COVID-associated pulmonary aspergillosis from Pakistan 巴基斯坦新冠肺炎相关肺曲霉病分离曲霉种对唑的耐药性筛选

10.01 - Respiratory infections and bronchiectasis Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.3858

S. Zaka, J. Farooqi, S. Faheem Naqvi, K. Jabeen, M. Irfan

引用次数: 0

Pre-COVID determinants of COVID-19 diagnosis by clinician and RT-PCR in a general adult population 普通成年人群中临床医生和RT-PCR诊断COVID-19的前决定因素

10.01 - Respiratory infections and bronchiectasis Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.2295

E. Quraishi, C. Jibuaku, D. Lisik, H. Kankaanranta, B. Nwaru

引用次数: 0

Long-term follow-up of SARS-CoV-2 IgM and IgG production in the patients with COVID-19 in Japan 日本COVID-19患者SARS-CoV-2 IgM和IgG的长期随访

10.01 - Respiratory infections and bronchiectasis Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.4451

T. Matsunaga, S. Ohta, F. Yamaguchi, K. Suzuki, A. Tanaka, I. Tokimatsu, H. Sagara

{"title":"Long-term follow-up of SARS-CoV-2 IgM and IgG production in the patients with COVID-19 in Japan","authors":"T. Matsunaga, S. Ohta, F. Yamaguchi, K. Suzuki, A. Tanaka, I. Tokimatsu, H. Sagara","doi":"10.1183/13993003.congress-2022.4451","DOIUrl":"https://doi.org/10.1183/13993003.congress-2022.4451","url":null,"abstract":"Introduction: It is known that Coronavirus disease 2019 (COVID-19) patients produce severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgM and IgG. However, the frequency and duration of the antibodies production are not fully understood. Aim and objectives: We aimed to investigate the production of SARS-CoV-2 IgM and IgG over 12 months and to verify the relationship with the characteristics of COVID-19 patients. Method(s): COVID-19 patients admitted to either of Showa University Hospital, Koto Toyosu Hospital, Fujigaoka Hospital, or Northern Yokohama Hospital, were enrolled for the study. The patients were followed up until they became negative for SARS-CoV-2 IgM and IgG or for up to 12 months after the date of SARS-CoV-2 PCR became negative. Result(s): Forty-five patients were enrolled, and 34 patients were followed up to the end. The positivity rates of SARSCoV-2 IgM and IgG were 27.3% and 68.2% when SARS-CoV-2 PCR was negative. The positivity rate of SARS-CoV2 IgG was 70.6%, 52.9%, 14.7%, 2.9% and 0.0% after 1, 3, 6, 9, and 12 months, respectively, after the date of PCR negativity. Moreover, we divided the patients into 2 groups;the milder conditions who did not require oxygen administration (non-severe group) and the severe conditions who required oxygen administration (severe group). The positivity rate of SARS-CoV-2 IgG was significantly higher in severe group compared to non-severe group on the date of PCR negativity and after 1 month, but no significant difference after 3 months. Conclusion(s): Present study suggested that more severe COVID-19 patients produced more SARS-CoV-2 IgG. However, the duration of SARS-CoV-2 IgG production was independent of COVID-19 severity.","PeriodicalId":420846,"journal":{"name":"10.01 - Respiratory infections and bronchiectasis","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116755714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Plasminogen activator inhibitor-1 (PAI-1) like the best mortality predictor of in the COVID-19-associated pneumonia 纤溶酶原激活物抑制剂-1 (PAI-1)可能是covid -19相关性肺炎的最佳死亡率预测因子

10.01 - Respiratory infections and bronchiectasis Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.2509

K. Bielosludtseva, T. Pertseva

引用次数: 2

COVID pneumoniae: Clinical and radiological follow-up of a prospective cohort 新冠肺炎:前瞻性队列的临床和放射学随访

10.01 - Respiratory infections and bronchiectasis Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.2733

A. Putruele, S. Resnik, E. A. Vallejos, F. Santtia, L. Barría, E. Perticone, F. Felder, M. Sosa, F. Nogueira, C. Luna

引用次数: 0

Longitudinal profiling of the peripheral blood transcriptome identifies risk of Major Cardiac Events after Hospitalization for COVID-19 外周血转录组的纵向分析可识别COVID-19住院后主要心脏事件的风险

10.01 - Respiratory infections and bronchiectasis Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.3087

C. Hughes, M. Long, H. Keir, Y. Giam, T. Pembridge, L. Delgado, H. Leyah, R. Hull, A. Gilmour, D. Cassidy, H. Richardson, A. Shoemark, F. Khan, J. Chalmers

引用次数: 0

Covid-19 and Cytokine Storm Covid-19和细胞因子风暴

10.01 - Respiratory infections and bronchiectasis Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.3255

L. López Vergara, L. Torralba, C. De Diego, A. Lasierra, R. Lahoz, C. Abadía, P. Ruiz De Copegui, J. Godino, A. Cebollada, B. Jimeno, S. Bello

{"title":"Covid-19 and Cytokine Storm","authors":"L. López Vergara, L. Torralba, C. De Diego, A. Lasierra, R. Lahoz, C. Abadía, P. Ruiz De Copegui, J. Godino, A. Cebollada, B. Jimeno, S. Bello","doi":"10.1183/13993003.congress-2022.3255","DOIUrl":"https://doi.org/10.1183/13993003.congress-2022.3255","url":null,"abstract":"Introduction: Covid-19 is associated with elevated proinflammatory cytokines that are associated with increased severity and mortality. There is controversy about the true role of cytokine storm (CS) in the pathophysiology of COVID-19. Method(s): Prospective, observational, longitudinal study of 91 hospitalized patients with different severity. It included Viral phase(1-9 days from clinical onset), early inflammatory (10-16 days), and late (>17 days). Clinical data, immune cell counts, proinflammatory cytokine levels (TNF-alpha,IL-1beta,IL-8,IL-6,INF-gamma,IL-17A andG-CSF), serum inflammatory markers (CRP,PCT,D-dimer,ferritin) and tissue damage markers (LDH and cfDNA) were included. Result(s): TNF- alpha, IL-8,IL-6 and G-CSF, were elevated in the most severe patients. IL-6, IL-8 and G-CSF were already elevated in the first admission sample in those who died. Only IL-6 remained elevated in all 3 phases of the disease in deceased patients. IL-1beta, INF-gamma and IL-17A were not related to severity. We found increased levels of cytokines from the viral phase to the early inflammatory phase, significant in moderate Covid-19, but stable in severe and decreasing in critically ill patients. Only IL-6 showed increasing levels in the evolution of critically ill patients. IL-6 correlated with the tissue damage markers studied and with length of stay, especially in critical patients (r=0.598). Conclusion(s): Only IL-6, TNF-alpha,IL-8 and G-CSF were associated with severity. IL-6 was the cytokine that best expressed hyperactivation of the innate immune response and cellular damage in critically ill. There was no significant and sustained increase in cytokines in late inflammation, as would be expected in major CS.","PeriodicalId":420846,"journal":{"name":"10.01 - Respiratory infections and bronchiectasis","volume":"90 1 Pt 1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129163822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Does the accuracy of clinician diagnosis of COVID-19 compared to RT-PCR in adults depend on the number and severity of comorbidities? 与RT-PCR相比，临床医生对成人COVID-19诊断的准确性是否取决于合并症的数量和严重程度?

10.01 - Respiratory infections and bronchiectasis Pub Date : 2022-09-04 DOI: 10.1183/13993003.congress-2022.1537

D. Lisik, C. Jibuaku, E. Quraishi, H. Kankaanranta, B. Nwaru

引用次数: 0